Add BrightSurf on Google Email

Gel-like, radioactive tumor implant obliterates pancreatic cancer in mice

Researchers at Duke University have developed a novel treatment that combines internal radiation and chemotherapy to eliminate tumors in 80% of mice with pancreatic cancer. The approach uses a gel-like depot implanted with radioactive iodine-131, which deposits beta radiation directly into the tumor without affecting surrounding tissue.

SourceDuke University·JournalNature Biomedical Engineering·TypeExperimental study·DateOct 20, 2022

Two drugs reverse key pancreatic cancer step in the lab

Scientists at the University of Florida have identified two small molecules that inhibit precancerous cell progression and reverse a key process involved in pancreatic cancer progression. This discovery could lead to earlier treatments and improved survival rates for patients with pancreatic cancer.

SourceUniversity of Florida·JournalCell Death Discovery·TypeExperimental study·DateOct 19, 2022

The use of high-throughput screening and high-content screening in anti-obesity drug discovery is investigated in the October issue of SLAS discovery

Few studies utilize high-throughput screening (HTS) and high-content screening (HCS) techniques in anti-obesity drug discovery due to a lack of original data or experimental design information. This limits the development of effective pharmaceutical treatments for obesity-related diseases.

Flatworm-inspired medical adhesives stop blood loss

Researchers from McGill University developed a medical adhesive inspired by flatworms that uses suction to absorb blood and promote blood coagulation. The adhesive can be removed without causing re-bleeding, making it a potential replacement for wound sutures or delivering drugs.

SourceMcGill University·JournalNature Communications·TypeExperimental study·DateOct 13, 2022

ProDERM study results of Octagam® 10% treatment in patients with dermatomyositis published in the New England Journal of Medicine

A large randomized clinical trial demonstrated Octagam 10% as an efficacious and well-tolerated treatment option for adult dermatomyositis patients. The study showed improved outcomes in patients with this rare disease, providing a much-needed treatment alternative.

SourceYankee Public Relations·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateOct 6, 2022

Study: Decreased proteins, not amyloid plaques, tied to Alzheimer’s disease

Researchers from the University of Cincinnati found that low levels of soluble amyloid-beta protein in the brain, rather than its buildup into plaques, are associated with cognitive decline and Alzheimer's disease. Patients with high levels of soluble amyloid-beta showed improved cognitive outcomes, contradicting previous theories.

SourceUniversity of Cincinnati·JournalJournal of Alzheimer’s Disease·TypeObservational study·DateOct 4, 2022

Obesity prevalence varies significantly for Asian American subgroups

A cross-sectional study of over 70,000 Asian Americans found significant variation in obesity prevalence among subgroups, with Filipino Americans having the highest rate at 28.7% and Chinese Americans the lowest at 13.2%. The study highlights the need for tailored strategies to address obesity disparities among Asian American populations.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeData/statistical analysis·DateOct 3, 2022

National Institutes of Health awards $15.75M to research team led by Case Western Reserve University and Duke University to map vagus nerve—body’s ‘super highway’ for controlling major organ functions

The researchers will conduct multimodal imaging of 100 human vagus nerves using high-resolution technologies, providing unprecedented data on the vagus nerve's organization. This work aims to improve the safety and effectiveness of existing vagus nerve therapies, offering potential for novel neuromodulation therapies.

EIP Pharma publishes translational data of preclinical and phase 2a results for Neflamapimod in dementia with Lewy bodies: Nature Communications

Neflamapimod, a p38α kinase inhibitor, demonstrates reversible neurodegeneration in animal models and improves clinical endpoints associated with cholinergic neuronal function in patients with dementia with Lewy bodies. The findings support the initiation of a confirmatory Phase 2b clinical trial for neflamapimod.

SourceLaVoieHealthScience·JournalNature Communications·TypeRandomized controlled/clinical trial·DateSep 21, 2022

New endoscope uses bendable GRIN lens for 3D microscopy

Researchers have developed a flexible endoscopic imaging probe using a bendable graded index (GRIN) lens, enabling 3D microscopic imaging of tissue. The new technology could shorten biopsy waiting times to minutes and enable real-time monitoring of tissue changes.

SourceOptica·JournalOptics Express·DateSep 21, 2022

Rheumatoid arthritis drug effective against myasthenia

A randomized clinical trial found that rituximab significantly improved disease control in patients with new-onset myasthenia gravis, reducing the need for cortisone treatments and hospitalizations. The study's results offer hope for a more effective treatment strategy, but larger studies are needed to assess long-term effects.

SourceKarolinska Institutet·JournalJAMA Neurology·TypeRandomized controlled/clinical trial·DateSep 19, 2022

Online yoga programs may improve knee function in the short term

A randomized trial found that a 12-week online yoga program improved knee function in participants, but did not significantly reduce knee pain during walking. The study suggests that unsupervised online yoga programs can be feasible and improve physical function, but more research is needed to sustain the effectiveness.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeRandomized controlled/clinical trial·DateSep 19, 2022

C-Path awarded FDA grant to establish public-private partnership to advance treatments for rare neurodegenerative diseases

The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.

Scientists have created a mathematical model for the dynamics of nanoparticles and viruses in cells

A team of scientists from Ural Federal University has developed a complex mathematical model to understand the dynamics of nanoparticles and viruses in cells. The model reveals how viruses cluster inside endosomes and interact with cellular proteins, shedding light on their behavior and replication mechanisms. This breakthrough can hel...

SourceUral Federal University·JournalCrystals·DateSep 13, 2022

Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate

A study by Case Western Reserve University has identified a promising path to developing therapies for esophageal tumors. The research team linked the TGFβ-pathway, a cell signaling mechanism, to tumor development and found that a protein-coding gene called HNF4α is a predictive biomarker of cancer.

SourceCase Western Reserve University·JournalGastroenterology·DateSep 7, 2022

Time’s arrow

Researchers found that brief rapamycin exposure in early adulthood can prevent age-related decline and extend lifespan. The study used fruit flies and mice to test the effects of short-term drug administration, showing protection against intestinal pathology and increased health span.

SourceMax Planck Institute for Biology of Ageing·JournalNature Aging·TypeExperimental study·DateAug 29, 2022

Early plasma antigen levels predict illness severity and clinical outcomes in hospitalized patients with COVID-19

A large cross-sectional study found that baseline plasma antigen levels are highly associated with both the severity of pulmonary illness and clinically important patient outcomes in hospitalized COVID-19 patients. Higher antigen levels were linked to increased risk of pulmonary worsening and delayed hospital discharge.

SourceAmerican College of Physicians·JournalAnnals of Internal Medicine·TypeObservational study·DateAug 29, 2022

ACC issues guidance to address new nonstatin therapies

The American College of Cardiology has published an expert consensus decision pathway on the role of nonstatin therapies for LDL-C lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk reduction. The guidance provides recommendations for individuals at high-risk and those with familial hypercholesterolemia, ...

SourceAmerican College of Cardiology·JournalJournal of the American College of Cardiology·TypeLiterature review·DateAug 25, 2022

New insights into the mechanisms behind Crohn’s disease point to potential therapeutic target

A new study by Massachusetts General Hospital researchers suggests that certain anti-cancer drugs may target a key player in Crohn's disease, a type of inflammatory bowel disease. The study found that mutations in a specific chromatin reader, SP140, are associated with an increased risk of immune diseases like Crohn's.

SourceMassachusetts General Hospital·JournalCell·TypeExperimental study·DateAug 22, 2022

Psychiatrists disagree with US policy on psychoactive drugs

A national survey of US psychiatrists found discrepancies between their perceptions of certain psychoactive drugs' safety and therapeutic value and how they are categorized under the Controlled Substances Act. Psychiatrists rated psilocybin as having low misuse potential and high therapeutic potential, but it is a Schedule I drug with ...

SourceOhio State University·JournalInternational Journal of Drug Policy·TypeSurvey·DateAug 22, 2022

Scientists create a DNA test that identifies Lyme disease in horses

A Rutgers scientist has developed a highly sensitive DNA test that can detect Lyme disease in horses, a condition that can cause long-term complications. The test, called genomic hybrid capture assay, was tested on a sick horse and successfully identified the pathogen, allowing for early diagnosis and treatment.

SourceRutgers University·JournalJournal of Veterinary Diagnostic Investigation·TypeExperimental study·DateAug 17, 2022

Prompt recognition and treatment found effective for lung disease in patients who received new drug for advanced cancer

A comprehensive analysis of interstitial lung disease diagnosis and treatment in patients who received an antibody drug conjugate known as T-DXd found that close monitoring and proactive management can reduce the risk of ILD. The study results suggest that patient awareness and ongoing education can aid in early detection.

PET scan visualization can measure effects of STING-activating drugs

Researchers have discovered a functional link between STING signaling and immunometabolism, suggesting that PET imaging could measure the pharmacodynamic effects of STING-activating drugs. This approach may enable a whole-body analysis of immune activation in humans, guiding clinical development of anti-tumor therapy.

SourceUniversity of California - Los Angeles Health Sciences·JournalJournal of Nuclear Medicine·TypeExperimental study·DateAug 10, 2022

Study identifies potential targets for treating venous ulcers

A study published in eLife identified three microRNAs that may impair healing in venous ulcers, a common type of chronic wound. The findings suggest that drugs targeting these microRNAs could help facilitate healing in patients, offering new approaches for treating this painful and slow-to-heal condition.

SourceeLife·JournaleLife·DateAug 9, 2022

Potential long-term treatment for asthma found

Researchers at Aston University have developed a new approach to tackle one of the underlying causes of asthma, not just its symptoms. The treatment, which targets the structural changes made by asthmatic airways, shows promising results in mice, reducing symptoms within two weeks and returning airways to near normal.

SourceAston University·JournalRespiratory Medicine·TypeExperimental study·DateAug 9, 2022

Researchers developed a small molecule that makes immunotherapy available to all cancer patients

Researchers developed a small molecule that effectively controls tumor growth by inhibiting PD-1/PD-L1 binding, overcoming accessibility and cost issues of existing antibody treatments. The new molecule has advantages in terms of affordability and oral administration, making immunotherapy more accessible to all cancer patients.

SourceTel-Aviv University·JournalJournal for ImmunoTherapy of Cancer·DateAug 8, 2022